EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy and safety of the muscarinic receptor agonist KarXT (Xanomeline-Trospium) in schizophrenia: a systematic review, meta-analysis and Bayesian sensitivity analysis

Nikhil Sharma, Mahalaqua N Khatib, Roopashree R, Mandeep Kaur, Manish Srivastava, Amit Barwal, Garbham Venkata Siva Prasad, Pranchal Rajput, Vinamra Mittal, Muhammed Shabil, Amit Kumar, Ganesh Bushi iD und 3 weitere

International Journal of Neuropsychopharmacology · 2026

DOI: 10.1093/ijnp/pyaf045 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Neuropsychopharmacology, 2026. Verfasst von Nikhil Sharma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, Guwahati 781101, India. Hauptthemen laut MEDLINE: Schizophrenia, Thiadiazoles, Benzilates, Antipsychotic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Schizophrenia significantly impacts global health, with existing treatments primarily focusing on positive symptoms and often causing considerable side effects. KarXT (Xanomeline-Trospium), a novel treatment combining xanomeline, a muscarinic M1/M4 receptor agonist, and trospium, targets a broader range of symptoms including negative and cognitive deficits, potentially with fewer side effects. This systematic review and meta-analysis evaluates the efficacy and safety of KarXT in treating schizophrenia, assessing symptom reduction and safety profiles compared to placebo.

Methods

We searched PubMed, Embase, and Web of Science up to November 10, 2024, for randomized controlled trials (RCTs) assessing the efficacy and safety of KarXT in schizophrenia. Data were pooled using a random-effects model, assessing outcomes like Positive and Negative Syndrome Scale (PANSS) scores and incidence of treatment-emergent adverse events (TEAEs). R software (Version 4.4.) was used for meta-analysis.

Results

Three RCTs involving 674 participants were included. KarXT significantly reduced total PANSS scores of mean difference (MD) –9.707 (95% CI: –12.329 to –7.085), with notable improvements in both negative (MD = –1.623; 95% CI: –2.461 to –0.785) and positive symptom subscales (MD = –3.213; 95% CI: –4.033 to –2.393). The treatment was associated with a higher incidence of TEAEs, predominantly constipation [risk ratio (RR): 2.77; 95% CI: 1.72–4.45] and nausea (RR: 4.87; 95% CI: 2.73–8.68) compared to placebo. Bayesian meta-analysis confirmed the results.

Conclusion

KarXT offers significant improvements in both negative and positive symptoms of schizophrenia with a manageable safety profile. Its potential as a transformative treatment for schizophrenia highlights the need for further research to confirm these findings and to fully understand its long-term efficacy and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaThiadiazolesBenzilatesAntipsychotic AgentsMuscarinic AgonistsPyridinesHumansBayes TheoremRandomized Controlled Trials as TopicTreatment OutcomeDrug CombinationsNortropanes

Stichwörter der Autor:innen

KarXTmeta-analysisrandomized controlled trialsschizophreniasystematic reviewtrospium xanomeline

Substanzen

ThiadiazolesxanomelineBenzilatestrospium chlorideAntipsychotic AgentsMuscarinic AgonistsPyridinesxanomeline, trospium drug combinationDrug CombinationsNortropanes

Autor:innen und Institutionen

  • Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, Guwahati 781101, India.
  • Division of Evidence Synthesis, Global Consortium of Public Health and Research, Datta Meghe Institute of Higher Education, Wardha, India.
  • Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
  • Department of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, Rajasthan 303012, India.
  • Department of Endocrinology, NIMS University, Jaipur, India.
  • Department of Pharmacy, Chandigarh Pharmacy College, Chandigarh Group of College, Jhanjeri, Mohali, Punjab 140307, India.

ORCID-Profile: Ganesh Bushi, Sanjit Sah

Zitieren

APA

Sharma, N., Khatib, M. N., R, R., Kaur, M., Srivastava, M., Barwal, A., Prasad, G. V. S., Rajput, P., Mittal, V., Shabil, M., Kumar, A., Bushi, G., Mehta, R., Satapathy, P., & Sah, S. (2026). Efficacy and safety of the muscarinic receptor agonist KarXT (Xanomeline-Trospium) in schizophrenia: a systematic review, meta-analysis and Bayesian sensitivity analysis. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyaf045

Vancouver

Sharma N, Khatib MN, R R, Kaur M, Srivastava M, Barwal A, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (Xanomeline-Trospium) in schizophrenia: a systematic review, meta-analysis and Bayesian sensitivity analysis. International Journal of Neuropsychopharmacology. 2026. doi:10.1093/ijnp/pyaf045

BibTeX
@article{Sharma2026,
  author = {Sharma, Nikhil and Khatib, Mahalaqua N and R, Roopashree and Kaur, Mandeep and Srivastava, Manish and Barwal, Amit and Prasad, Garbham Venkata Siva and Rajput, Pranchal and Mittal, Vinamra and Shabil, Muhammed and Kumar, Amit and Bushi, Ganesh and Mehta, Rachana and Satapathy, Prakasini and Sah, Sanjit},
  title = {Efficacy and safety of the muscarinic receptor agonist KarXT (Xanomeline-Trospium) in schizophrenia: a systematic review, meta-analysis and Bayesian sensitivity analysis},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2026},
  doi = {10.1093/ijnp/pyaf045}
}
Kostenlos starten →